Health & Fitness
Mon, February 13, 2012
LINCOLNSHIRE, Ill.--([ BUSINESS WIRE ])--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, BioSanteas president & CEO will present a corporate update at the BIO CEO & Investor Conference on Tuesday, February 14, 2012 at 10:30 am EST in New York City.
A live audio webcast of remarks by Mr. Simes may be accessed at [ http://www.veracast.com/webcasts/bio/ceoinvestor2012/76206341.cfm ]. The webcast will be archived for 90 days.
The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Information about the conference is available at [ http://www.bio.org/events/conferences/14th-annual-bio-ceo-investor-conference ].
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's products include LibiGel(transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development. BioSante also is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA). BioSanteas other products include Bio-T-Gela", a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) is pending, which is licensed to Teva Pharmaceuticals, and the Pill-Plusa", an oral contraceptive in Phase II clinical development by Pantarhei Bioscience B.V. BioSante's first FDA-approved product is Elestrina" (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Jazz Pharmaceuticals, BioSante's licensee. Additional information is available online at: [ www.biosantepharma.com ].
